New rabies vaccine shows promise in large thai trial

NCT ID NCT04478084

Completed ⭐️ VACCINE ⭐️ Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tested a new rabies vaccine called VRVg-2 in 403 healthy volunteers in Thailand. The study compared two different vaccination schedules and also looked at combining the vaccine with rabies antibodies (immunoglobulins). The goal was to see if the new vaccine produces enough protective antibodies and is safe. Results are not yet available, but this could lead to a more modern rabies vaccine option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Purified vero rabies vaccine (VRVg-2)
What this could lead to: If successful, this could provide a safer, equally effective alternative to current rabies vaccines, potentially improving access and reducing side effects.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The vaccine may not work as well as existing ones, and side effects are possible. The study was done in healthy volunteers, not actual rabies exposures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES (HEALTHY VOLUNTEERS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rabies prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RABIES (HEALTHY VOLUNTEERS)

Contacts and locations

Locations

Investigational Site Number :7640002

Bangkok, Thailand
Investigational Site Number :7640003

Khon Kaen, 40002, Thailand
Investigational Site Number :7640004

Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.